Easterly Government Props Azioni (NYSE: DEA)

Ultime notizie per Easterly Government Props (NYSE:DEA) Azioni

Easterly Government Props

Easterly Government Properties Inc is a real estate investment trust. It is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. The company generates all its revenue by leasing its properties to such agencies.

News

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

CLPR

Scopri le 3 azioni immobiliari con dividendi sopra il 7% consigliate dagli analisti di Wall Street per settembre.

3 azioni con dividendi sopra il 7% consigliate da Wall Street

Scopri i 3 migliori titoli immobiliari con dividendi oltre il 7% consigliati da Wall Street per investimenti redditizi.

3 titoli immobiliari con dividendi superiori al 7% consigliati da Wall Street

Easterly Government Properties, Inc. Common Stock

Easterly Government Properties Inc

DEAPcoin

DEALERADVANCE INC NEW by DealerAdvance, Inc.

DealerAdvance Inc

DEAR CASHMERE HOLDING CO by Dear Cashmere Holding Co.

Dear Cashmere Holding Co

Village Farms International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) and Hemp for Victory filed a joint motion seeking to disqualify the Drug Enforcement Administration (DEA) from defending the proposed rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act.
The parties argue that the DEA is compromised and opposes the rescheduling, suggesting its role should be taken by the Department of Justice (DOJ) to ensure an impartial process.
"It is our belief that the DEA cannot lawfully act as the proponent of the Proposed Rule and that its actions throughout the administrative process demonstrate that it opposes the proposed transfer of marijuana to Schedule III and is therefore compromised," Shane Pennington, partner at Porter Wright Morris &amp; Arthur, LLP and counsel to Village Farms and Hemp for Victory commented, "Treating the DEA as the proponent of the Proposed Rule would violate APA and DEA regulations and render these proceedings a sham. Lawyers from the Department of Justice, not the Drug Enforcement Administration, must therefore defend this rule."
In August 2023, Health and Human Services (HHS) Secretary Xavier Becerra confirmed his agency responded to President Biden&#8217;s directive to provide scheduling recommendations for cannabis to the DEA. HHS <a href="https://www.benzinga.com/markets/cannabis/23/08/34126690/hhs-secretary-confirms-it-is-recommending-cannabis-be-rescheduled-per-bidens-directive">called for marijuana to be reclassified as a Schedule III drug</a> under the Controlled Substances Act.
The <a href="https://villagefarms.com/wp-content/uploads/2024/11/Hemp-for-Victory-and-Village-Farms-Motion-to-Disqualify-and-Supplement-Record-with-Exhibits-A-C.pdf">motion</a> argues that "Not once in its history as an agency had DEA ever rejected an HHS scheduling recommendation. This time, however, DEA did not just disagree with HHS's views, it opposed them so vehemently that the Attorney General had to refer the interagency dispute to the Office of Legal Counsel for resolution."
Read Also: <a href="https://www.benzinga.com/general/health-care/24/11/42077935/trump-picks-dr-oz-who-says-seniors-should-give-medical-marijuana-a-try-to-lead-centers-for-medicare-and-medicaid-services">Trump Picks Dr. Oz, Who Says Seniors Should Give Medical Marijuana A Try, To Lead Centers For Medicare And Medicaid Services</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h2 class="wp-block-heading">Calling For Transparency</h2>
The motion also asks that the record include all requests for hearing and/or participation in these proceedings filed with the DEA; a record of the decisions made by the Administrator regarding why certain parties were designated as participants and others were not; and any ex parte communications between DEA and third parties.
"Without knowing who DEA excluded and why, there is no way to assess whether and to what extent the Agency's decisions are arbitrary and capricious, the subject of bias, or otherwise unlawful," reads the filing. "If, for example, DEA included parties with expertise on a particular topic but only if they opposed the Proposed Rule while also excluding parties with even more expertise on that same topic if they supported the Proposed Rule, then there would be a powerful case to be made that the Agency's decisions were arbitrary and capricious."
Among 25 participants that DEA chose to join the hearing on rescheduling cannabis is Smart Approaches To Marijuana (SAM), an organization opposed to marijuana legalization and commercialization. On the other hand, Village Farms is <a href="https://www.benzinga.com/markets/cannabis/24/11/41726679/village-farms-is-only-cannabis-operator-selected-to-represent-weed-industry-at-dea-rescheduling-">the only cannabis operator selected to represent cannabis industry</a>.
Village Farms and Hemp for Victory also require that SAM and the DEA be ordered to preserve their records, as factual evidence demonstrates unlawful conduct which has further compromised the DEA's participation in the proceedings.
Michael DeGiglio, retired Navy captain and naval aviator and president and chief executive officer of Village Farms concluded, "Our organization embraces the power of the cannabis plant as an alternative to Big Pharma and harmful, addicting drugs like opioids. However, we continue to face burdensome challenges in several of our regulatory jurisdictions that not only restrict us from advancing access to cannabis for millions of people, but have also created near-insurmountable institutional barriers to clinical research involving cannabis. We are proud to be one of the pro-cannabis participants selected to testify as a witness in the upcoming Rescheduling Hearing, but the filing of this joint motion reflects our desire for a more transparent process that ensures all credible voices are heard, including other applicants whose expertise has been overlooked or ignored."
<h2 class="wp-block-heading">DEA Under Attack</h2>
The motion follows a lawsuit by a Washington-based researcher filing a <a href="https://www.benzinga.com/news/legal/24/11/41923948/dea-faces-lawsuit-alleging-bias-in-marijuana-rescheduling-process">lawsuit against the DEA alleging multiple legal violations</a> in the agency&#8217;s process of <a href="https://www.benzinga.com/topic/cannabis-rescheduling" target="_blank" rel="noreferrer noopener">rescheduling marijuana</a>. David Heldreth, CEO of psychedelic research firm Panacea Plant Sciences, claims the DEA&#8217;s recent actions violate federal law and constitutional principles. Despite submitting a request to participate in the hearings, Heldreth&#8217;s company, Panacea Plant Sciences, was excluded from the list of 25 participants chosen by Milgram. This exclusion is at the heart of Heldreth&#8217;s lawsuit, which accuses the DEA of bias and of sidelining critical voices in favor of larger, established players in the industry.
Moreover, the Veterans Action Council (VAC), a cannabis advocacy organization for military vets, <a href="http://drugsense.org/temp/VACXPRESSXXRELEASE_X14XNovemberXX2024.pdf?fbclid=IwZXh0bgNhZW0CMTAAAR1wzl2RC2z5p-kEiG9p4J03gHKGhie0JyDYxWJx3SdVSeDA7a_6WeEXL3Y_aem_ANUFL62rwPZ-jy58Hyw9-A" target="_blank" rel="noreferrer noopener">filed a petition</a> also <a href="https://www.benzinga.com/news/legal/24/11/42068859/veterans-group-challenges-dea-for-seat-at-cannabis-debate-table">challenging its exclusion</a> from the DEA&#8217;s participant list. VAC contends that the DEA failed to meet its obligation to include all interested parties. &#8220;The DEA was tasked with putting forward a group of ‘interested parties.&#8217; They failed to do so, as illustrated by the judge&#8217;s recent order,&#8221; said VAC&#8217;s Michael Krawitz.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/06/39215651/dea-ditches-high-level-federal-health-meeting-on-cannabis-research-another-expression-of-distast">DEA Ditches High-Level Federal Health Meeting On Cannabis Research: Another Expression Of Distaste For Cannabis Rescheduling?</a></li>
</ul>
Photo: Courtesy of RazorMax and ganjaspliffstoreuk to Pixabay

Cannabis

DEA Is Compromised, DOJ Should Replace It In Cannabis Rescheduling, Claims Joint Motion

The Drug Enforcement Administration (DEA) may consider additional participants for its marijuana rescheduling hearings following a Nov. 15 order by chief administrative law judge (ALJ) John J. Mulrooney II. As MJBiz Daily <a href="https://mjbizdaily.com/dea-hints-more-marijuana-rescheduling-participants-possible/">reported</a>, this development follows the withdrawal of some designated participants and growing scrutiny over the agency&#8217;s handling of the rescheduling process, which has now been delayed until 2025.
<h3 class="wp-block-heading">Veterans Group Demands Inclusion</h3>
The Veterans Action Council (VAC), a cannabis advocacy organization for military vets, <a href="http://drugsense.org/temp/VACXPRESSXXRELEASE_X14XNovemberXX2024.pdf?fbclid=IwZXh0bgNhZW0CMTAAAR1wzl2RC2z5p-kEiG9p4J03gHKGhie0JyDYxWJx3SdVSeDA7a_6WeEXL3Y_aem_ANUFL62rwPZ-jy58Hyw9-A">filed a petition</a> challenging its exclusion from the DEA's <a href="https://es.scribd.com/document/786777188/DEA-administrator-AnneMilgram-Names-ALJ-25-Hearing-participants-CannabisRescheduling">participant list</a>, which was released in October. VAC contends that the DEA failed to meet its obligation to include all interested parties. "The DEA was tasked with putting forward a group of ‘interested parties.' They failed to do so, as illustrated by the judge's recent order," said VAC's Michael Krawitz.
The DEA had initially planned for the hearings to begin on Dec. 2, 2024, but Mulrooney clarified that no testimony or evidence would be received on that date. Instead, the initial hearing will focus on scheduling participant availability for 2025. Mulrooney's <a href="https://es.scribd.com/document/786776020/DOJ-ALJ-JohnMulrooney-CannabisRescheduling-HearingOrder">Oct. 31 order</a> criticized the lack of clarity regarding participants' positions on the proposed rescheduling of cannabis from Schedule I to Schedule III.
"There is no indication in the four corners of the document as to whether the ‘participants' support or oppose the [rulemaking proposal] or how the ‘participants' satisfy the ‘interested person' definition set forth in the regulations," Mulrooney wrote, requiring additional details from participants by Nov. 12.
On November 15, Mulrooney <a href="https://www.documentcloud.org/documents/25337999-dea-vca-response-marijuana-rescheduling?responsive=1&amp;title=1">rejected VAC's request</a>, explaining that because the VAC was not included on Milgram's list, &#8220;no action can or will be taken on its request.&#8221; However, he also suggested that the matter might not be completely closed. In his ruling, he referenced a legal precedent indicating that decisions about participation could still be appealed. &#8220;The issue may not be entirely settled,&#8221; the judge wrote in a footnote, citing a case where a subpoena decision was not final until the case was fully resolved.
&#8220;He didn't completely shut it down,&#8221; Krawitz told MJBiz Daily, suggesting that the VAC could pursue other legal avenues.
<h3 class="wp-block-heading">Advocating For Descheduling</h3>
VAC is advocating for either cannabis descheduling or its classification under Schedule 5, the least restrictive category under DEA jurisdiction, rather than the proposed Schedule 3. According to VAC, Schedule 5, or descheduling, better reflects the realities of a $32 billion cannabis industry and its economic and medicinal significance.
"Schedule 5, if not descheduling entirely, is more appropriate for a $32 billion legal cannabis industry," Krawitz stated in the petition. Moving cannabis to Schedule 3 would alleviate some tax burdens under Section 280E of the tax code, but critics argue it still places cannabis in an inappropriate category alongside FDA-approved prescription drugs.
<h3 class="wp-block-heading">Changes To The Participant List</h3>
Several organizations have withdrawn from the hearings since the original list was announced. The American College of Occupational and Environmental Medicine missed procedural deadlines, while an oncologist representing the American Academy of Hospice and Palliative Medicine declined to participate. Meanwhile, five of the remaining participants share legal representation by David Evans, a noted anti-cannabis advocate, illustrating the polarized nature of the hearings.
<h3 class="wp-block-heading">Crucial Decision Delayed</h3>
The DEA's rescheduling process originates from President Joe Biden's 2022 directive to review cannabis's classification. In 2023, the Department of Health and Human Services (HHS) recommended reclassifying cannabis to Schedule III, citing accepted medical use. Despite the recommendation, the DEA retains ultimate authority to determine the plant's schedule under the Controlled Substances Act.
The hearings, now delayed to early 2025, pushed the DEA's final decision beyond the Biden administration. The inclusion of additional voices, particularly from groups like VAC, could influence the outcome of the hearings and shape the future of federal cannabis regulation.
Cover image made with AI

Government

Legal

Veterans Group Challenges DEA For Seat At Cannabis Debate Table

Guidance
This guidance is forward-looking and reflects management's view of current and future market conditions. The Company's actual results may differ materially from this guidance.
Outlook for the 12 Months Ending December 31, 2024
The Company is maintaining its guidance for full-year 2024 Core FFO per share on a fully diluted basis at a range of $1.15 - $1.17.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">Low</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">High</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net income (loss) per share – fully diluted basis</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">0.22</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">0.24</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Plus: Company's share of real estate depreciation and amortization</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">0.92</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">0.92</td>
</tr>
<tr>
<td colspan="1" rowspan="1">FFO per share – fully diluted basis</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">1.14</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">1.16</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Plus: Company's share of depreciation of non-real estate assets</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">0.01</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">0.01</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Core FFO per share – fully diluted basis</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">1.15</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">1.17</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;

Earnings

Guidance

Easterly Government Properties Reaffirms Its Guidance For 2024 Core FFO per share of $1.15 - $1.17 Vs. $1.15 Est.

Easterly Government Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEA#NYSE">DEA</a>) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.29 by 3.45 percent. This is a 3.45 percent increase over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $74.781 million which missed the analyst consensus estimate of $76.703 million by 2.51 percent. This is a 3.84 percent increase over sales of $72.014 million the same period last year.

Earnings Beats

Earnings Misses

Easterly Government Props Q3 2024 FFO $0.30 Beats $0.29 Estimate, Sales $74.781M Miss $76.703M Estimate

A legal dispute has erupted in Allen, Texas, where cannabis shop owners and their advocates are taking a stand against local and federal law enforcement, claiming their rights were violated during <a href="https://www.benzinga.com/markets/cannabis/24/05/38826163/freedoms-just-another-word-for-losing-2-000-cannabis-plants-in-maine-police-raid">recent police raids. </a>
This lawsuit, filed by attorney David Sergi on Oct. 24, represents Sabhie Khan, a manager of Allen Smoke and Vape, and members of the Hemp Industry Leaders of Texas, following an August raid led by the Allen Police Department with the support of the U.S. Drug Enforcement Administration (DEA).
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41521360/8b-market-on-the-brink-texas-senator-calls-it-uncontrollable-proposes-erasing-hemp">$8B Market On The Brink: Texas Senator Calls It &#8216;Uncontrollable,&#8217; Proposes Erasing Hemp</a>
Sergi condemned the raids as "fishing expeditions," saying "the DEA attempted to intimidate and bully these family businesses selling legal hemp," Lonestar Live <a href="https://www.lonestarlive.com/news/2024/10/cannabis-lawyer-claims-dea-tried-to-intimidate-and-bully-texas-smoke-shop-owners-in-new-lawsuit.html">reported</a>.
He contends that law enforcement's actions crossed a line, disregarding Texas&#8217;s hemp regulations and constitutional protections. Under Texas law, cannabis products with 0.3% delta-9 THC or less qualify as hemp, making them lawful within the state.
<h3 class="wp-block-heading">Raids And Arrests Spark Lawsuit</h3>
The incident that sparked the lawsuit occurred on Aug. 27, when Allen Police, collaborating with federal agencies, searched several shops, arresting Khan. The lawsuit alleges he was charged with a second-degree felony for "manufacturing a controlled substance" despite the seized products meeting Texas's legal definition of hemp.
According to Sergi, Khan, who is 70, was jailed for two days, "shackled in a jail cell without bond," despite his business being in compliance with state hemp laws. Sergi criticized the enforcement agencies' handling of Khan's case, saying they treated him "like the kingpin of a drug cartel, despite hemp being legal."
The plaintiffs argue that their Fourth, Fifth, Eighth, and 14th Amendment rights were breached in the process, naming the city of Allen, the Allen Police Department, Police Chief Steve Dye, Collin County Sheriff Jim Skinner and the DEA in the lawsuit. These amendments offer protections against unreasonable searches, self-incrimination, and cruel punishment, as well as guaranteeing due process.
<h3 class="wp-block-heading">Legal Battles And Disputed Testing Methods</h3>
The trouble began in May when Allen police allegedly sent notices to several CBD and vape shops, accusing them of selling "illegal THC products." The lawsuit claims the DEA followed suit in June, issuing subpoenas to Khan and other business owners, demanding sensitive personal and business data.
A federal judge issued a temporary stay on these subpoenas in July, questioning their legitimacy. However, the lawsuit alleges that the DEA sidestepped this judicial halt by engaging the Allen Police Department, who executed search warrants under allegedly flawed "questionable laboratory testing methods and standards" that could not differentiate between delta-9 THC and other legal cannabinoids in the products.
Sergi contends that these actions led to the seizure of approximately $8,000 to $10,000 worth of "legal inventory," with much of it being delta-8, THCa, and THCP products, all of which had certificates of analysis, a legal requirement for hemp products in Texas. 
Additionally, officers allegedly confiscated computers, phones and storage devices from Khan's shop, significantly impacting his business operations.
<h3 class="wp-block-heading">Calls For Legal Protections And Industry Standards</h3>
Khan and his fellow plaintiffs are not only seeking the immediate return of seized inventory and compensation for damages but are also requesting a permanent injunction to protect their businesses from future "unlawful actions." 
The lawsuit demands that any future testing on hemp products employ high-performance liquid chromatography (HPLC) to ensure compliance with Texas's legal standards, especially concerning the preservation of THCa, which Texas law treats differently from delta-9 THC.
The Allen Police Department has yet to issue a public response, citing "pending litigation." The outcome of this lawsuit could significantly impact Texas's hemp industry, as Khan and other business owners advocate for greater legal clarity and protections, insisting on their right to operate without undue interference from law enforcement.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41198379/texas-hemp-industry-fights-delta-8-thc-ban-as-supreme-court-decision-looms">Texas Hemp Industry Fights Delta-8 THC Ban As Supreme Court Decision Looms</a></li>
</ul>
Cover image made with AI.

Texas Smoke Shop Owners Sue DEA Over 'Intimidation And Bullying' Tactics In Raid Of Legal Retail Store

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the real estate sector.
<h3 class="wp-block-heading">Easterly Government Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEA#NYSE">DEA</a>)</h3>
<ul>
<li>Dividend Yield: 7.64%</li>
<li>Truist Securities analyst Michael Lewis maintained a Hold rating and raised the price target from $13 to $14 on Aug. 29. This analyst has an accuracy rate of 71%.</li>
<li>RBC Capital analyst Michael Leithead Carroll downgraded the stock from Sector Perform to Underperform and cut the price target from $15 to $13 on Aug. 16, 2023. This analyst has an accuracy rate of 63%.</li>
<li>Recent News: Easterly Government Properties will release its third quarter 2024 financial results on Nov. 5.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102524&amp;t=be2bearmibe3na1">latest DEA news.</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="912" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25091804/image-256.png" alt="" class="wp-image-614448" style="width:746px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25091804/image-256.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25091804/image-256-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25091804/image-256-768x705.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<h3 class="wp-block-heading">EPR Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPR#NYSE">EPR</a>)</h3>
<ul>
<li>Dividend Yield: 7.26%</li>
<li>JP Morgan analyst Anthony Paolone maintained an Overweight rating and raised the price target from $48 to $51 on Sept. 9. This analyst has an accuracy rate of 66%.</li>
<li>Truist Securities analyst Ki Bin Kim maintained a Hold rating and boosted the price target from $44 to $46 on Aug. 16. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: EPR Properties will release its third quarter 2024 financial results after closing bell on Wednesday, Oct. 30.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102524&amp;t=be2bearmibe3na1">latest EPR news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="812" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25091839/image-257.png" alt="" class="wp-image-614450" style="width:735px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25091839/image-257.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25091839/image-257-300x269.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25091839/image-257-768x688.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">OUTFRONT Media Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUT#NYSE">OUT</a>)</h3>
<ul>
<li>Dividend Yield: 6.46%</li>
<li>JP Morgan analyst Richard Choe maintained a Neutral rating and raised the price target from $17 to $18 on July 31. This analyst has an accuracy rate of 62%.</li>
<li>TD Cowen analyst Lance Vitanza initiated coverage on the stock a Hold rating with a price target of $16 on July 16. This analyst has an accuracy rate of 79%.</li>
<li>Recent News: OUTFRONT Media will report results for the fiscal quarter ended Sept. 30, after the market closes on Tuesday, Nov. 5.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102524&amp;t=be2bearmibe3na1">trend in OUT stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="912" height="830" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25091913/image-258.png" alt="" class="wp-image-614453" style="width:700px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25091913/image-258.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25091913/image-258-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25091913/image-258-768x699.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41528323/jim-cramer-says-hold-on-to-palantir-let-them-walk-it-up-warns-that-travere-therapeutics-is-losing-a">Jim Cramer Says &#8216;Hold On&#8217; To Palantir, &#8216;Let Them Walk It Up&#8217;; Warns That Travere Therapeutics Is Losing A &#8216;Ton Of Money&#8217;</a></li>
</ul>

Wall Street's Most Accurate Analysts Give Their Take On 3 Real Estate Stocks Delivering High-Dividend Yields

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2024/10/16/final-trades-transdigm-easterly-government-booz-allen-and-oneok.html">Halftime Report Final Trades</a>,&#8221; Stephen Weiss of Short Hills Capital Partners named TransDigm Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>) as<a href="https://www.benzinga.com/quote/TDG/analyst-ratings"> his final trade</a>.
On Monday, JPMorgan analyst Seth Seifman maintained TransDigm with a Neutral and raised the price target from $1435 to $1555.
Jenny Van Leeuwen Harrington of Gilman Hill Asset Management said Easterly Government Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEA#NYSE">DEA</a>) has a 7.5% dividend yield. Jefferies also upgraded the stock recently from Hold to Buy and raised the price target from $13 to $15, she added.
Easterly Government Properties will release its third quarter financial results on Nov. 5. Analysts expect the company to report quarterly earnings at 5 cents per share on revenue of $76.7 million.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Kari Firestone of Aureus Asset Management picked Booz Allen Hamilton Holding Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>).
On Oct. 10, Goldman Sachs analyst Gavin Parsons maintained Booz Allen Hamilton with a Buy and raised the price target from $174 to $196.
Joseph M. Terranova of Virtus Investment Partners named ONEOK, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>) as his final trade.
On Wednesday, RBC Capital analyst Elvira Scotto maintained ONEOK with a Sector Perform rating and raised the price target from $89 to $98. The board of directors of ONEOK also declared a quarterly dividend of 99 cents per share, unchanged versus the previous quarter.
Price Action:
<ul>
<li>TransDigm Group fell 0.5% to close at $1,384.07 during Wednesday's session.</li>
<li>Easterly Government Properties shares rose 2.9% to settle at $14.35 on Wednesday.</li>
<li>Booz Allen Hamilton shares gained 1.1% to settle at $164.13 on Wednesday.</li>
<li>ONEOK shares gained 0.7% to close at $95.65.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41366043/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields</a></li>
</ul>
Image: Wikimedia Commons

Long Ideas

Media

TransDigm, Easterly Government Properties, Booz Allen Hamilton And An Energy Stock On CNBC's 'Final Trades'

CNBC Final Trades: TransDigm, Easterly Government Properties, Booz Allen Hamilton, Oneok

~ 100% leased, triple net asset with annual rent escalations ~
Easterly Government Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEA#NYSE">DEA</a>) (the "Company" or "Easterly"), a fully integrated real estate investment trust focused primarily on the acquisition, development and management of Class A commercial properties leased to the U.S. Government and its adjacent partners, announced today that it has acquired a 104,136 square foot facility 100% leased to Northrop Grumman Systems Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>, S&amp;amp, , P: BBB+)))), a multinational aerospace and defense company, located in Aurora, Colorado ("Northrop Grumman - Aurora").
The facility, developed in 2002, was built-to-suit for TRW Inc., an aerospace and automotive corporation acquired by Northrop Grumman in that same year. Approximately 70% of the three-floor buildout is constructed under secure design standards as required by the U.S. Government related to the tenant's contracts with Buckley Space Force Base ("Buckley SFB"). This secure space is certified and accredited as meeting Director of National Intelligence security standards for the processing, storage, and discussion of sensitive compartmented information.

Easterly Government Properties Acquires 104,136 SF Facility Adjacent To Buckley Space Force Base And Occupied By Northrop Grumman Systems Corporation; No Financial Terms Disclosed

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/63c6ba8b5750940001b7cb04/jake-roberge">William Blair analyst Jake Roberge</a> upgraded the rating for Elastic N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) from Market Perform to Outperform. Elastic shares gained 1.2% to close at $83.00 on Friday. <a href="https://www.benzinga.com/quote/ESTC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Rob Owens upgraded SentinelOne, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) from Neutral to Overweight and raises the price target from $25 to $32. SentinelOne shares fell 0.5% to close at $25.71 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Daniel Rizzo upgraded AptarGroup, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATR#NYSE">ATR</a>) from Hold to Buy and raised the price target from $155 to $215. AptarGroup shares gained 1.5% to close at $161.55 on Friday. <a href="https://www.benzinga.com/quote/ATR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group analyst Chris McNally upgraded the rating for BorgWarner Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWA#NYSE">BWA</a>) from In-Line to Outperform and boosted the price target from $39 to $43. BorgWarner shares gained 0.5% to close at $35.05 on Friday. <a href="https://www.benzinga.com/quote/BWA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Peter Abramowitz upgraded Easterly Government Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEA#NYSE">DEA</a>) from Hold to Buy and raised the price target from $13 to $15. Easterly Government Properties shares gained 0.8% to close at $13.27 on Friday. <a href="https://www.benzinga.com/quote/DEA/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ESTC stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="500" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14090802/image-98-1024x500.png" alt="" class="wp-image-593848" style="width:541px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14090802/image-98-1024x500.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14090802/image-98-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14090802/image-98-768x375.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14090802/image-98.png 1361w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41308141/this-analyst-with-85-accuracy-rate-sees-around-20-upside-in-amd-here-are-5-stock-picks-for-last-week">This Analyst With 85% Accuracy Rate Sees Around 20% Upside In AMD &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Upgrades

ESTC

This Elastic Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

Jefferies analyst Peter Abramowitz upgrades Easterly Government Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEA#NYSE">DEA</a>) from Hold to Buy and raises the price target from $13 to $15.

Jefferies Upgrades Easterly Government Props to Buy, Raises Price Target to $15

Top Democrats from influential House committees are urging the Drug Enforcement Administration (DEA) to expedite the process of <a href="https://www.benzinga.com/topic/cannabis-rescheduling">rescheduling cannabis.</a>
In a letter sent to Attorney General Merrick Garland and DEA Administrator Anne Milgram, Representatives Jerrold Nadler (D-NY) and Frank Pallone (D-NJ), ranking members of the Judiciary and Energy &amp; Commerce Committees respectively, stressed the need for quick action following a scientific review by the Biden administration.
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40938172/no-turning-back-now-cannabis-rescheduling-gains-momentum-expert-offers-timeline">&#8216;No Turning Back Now&#8217;: Cannabis Rescheduling Gains Momentum, Expert Offers Timeline</a>
According to <a href="https://www.marijuanamoment.net/top-congressional-democrats-push-dea-to-swiftly-reschedule-marijuana-and-continue-to-assess-full-legalization/">Marijuana Moment</a>, the lawmakers argue that cannabis has &#8220;less potential for abuse than other drugs&#8221; and serves an &#8220;accepted medical use in treatment.&#8221;
Their comments align with recommendations from the Department of Health and Human Services (HHS) and the Department of Justice, which have called for the reclassification of cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA).
&#8220;We value the Department of Justice's steadfast commitment to prevent the misuse and diversion of controlled substances that pose a threat to public health," Nadler and Pallone wrote.
The lawmakers applauded the Biden administration for initiating the review and urged the DEA to &#8220;swiftly complete this process and transfer marijuana to schedule III.&#8221;
<h3 class="wp-block-heading">Push For Full Descheduling</h3>
While the immediate focus is on rescheduling to Schedule III, which would loosen some federal restrictions on cannabis, the legislators also urged federal agencies to explore further reform. 
They said that &#8220;continuing to assess whether schedule IV, schedule V, or descheduling may be appropriate&#8221; could be the next step in aligning cannabis policy with evolving scientific and medical understanding. 
Descheduling, which would remove cannabis from the CSA entirely, remains a key objective for many advocates and lawmakers, including Nadler, who has previously sponsored the MORE Act &#8211; a bill that would result in full legalization.
<h3 class="wp-block-heading">Election-Year Focal Point</h3>
The timing of the lawmakers' push comes as cannabis policy increasingly takes center stage in <a href="https://www.benzinga.com/markets/cannabis/24/09/40785015/harris-campaign-accuses-trump-of-blatant-pandering-and-lying-about-his-cannabis-support-announce">U.S. election politics.</a> Both major parties are positioning themselves on the issue as the 2024 presidential election approaches. 
However, final action on the rescheduling is not expected until after November, with the DEA scheduling an administrative hearing on the matter for December 2. This hearing will allow for further input from experts and stakeholders before the agency potentially finalizes its decision.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/41015020/dea-boosts-psychedelics-production-for-research-cannabis-quotas-hold-steady-ahead-of-reschedulin">DEA Boosts Psychedelics Production For Research, Cannabis Quotas Hold Steady Ahead Of Rescheduling</a></li>
</ul>

Regulations

Politics

House Democrats Urge DEA To Speed Up Cannabis Rescheduling

Edwin Rubis has served 27 years of a 40-year federal prison sentence after being convicted on non-violent cannabis related charges in the late 1990s. Cannabis and criminal justice reform advocates are rallying for his release by way of a presidential pardon from the <a href="https://www.benzinga.com/topic/biden-administration">Biden Administration</a>.
Rubis, now 56, was 29 years old with one child and another on the way in 1998 when the DEA arrested him and charged him with conspiracy to distribute cannabis. No drugs, guns or money were found in Edwin&#8217;s possession. Still, he was found guilty and sentenced to 40 years.
In the 27 years he has served so far, Rubis has been an exemplary inmate earning three college degrees and completing 30+ rehabilitation programs. Without government intervention, his earliest release date is not until 2031 when he will be 63 years old.
&#8220;I no longer belong in prison. I am not a threat to society. The Bureau of Prisons has categorized me as a low non-violent offender for recidivism purposes. I am a non-violent cannabis offender. I believe in redemption," Rubis <a href="https://www.prnewswire.com/news-releases/who-is-edwin-rubis-getting-to-know-the-man-serving-a-40-year-sentence-for-non-violent-cannabis-charges---beard-bros-media-302245867.html">said</a> in a <a href="https://drupal-cloudfront.benzinga.com/topic/beard-bros-pharms-0">Beard Bros Pharm</a> press release. "I am a compassionate and relatable individual who does not judge others by their culture, creed, or religion, but by the intentions of their heart. I am honest and loyal; responsible and accountable. I deserve a second chance at life.&#8221;
His parents are in their 80s and Edwin wants to see them again. His three adult children have been deprived of their father&#8217;s presence for most of their lives, noted Beard Bros, a legacy brand and media outlet calling on President Joe Biden to grant a full pardon and release Rubis from federal prison.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40867166/federal-marshals-raid-legal-medical-marijuana-shop-in-texas-why-the-big-guns-advocates-say-its-a">Federal Marshals Raid Legal Medical Marijuana Shop In Texas: Why The Big Guns? Advocates Say &#8216;It&#8217;s Absurd&#8217;</a>
<h2 class="wp-block-heading">Biden&#8217;s Unfulfilled Promise </h2>
October 6, 2022, <a href="https://www.benzinga.com/markets/cannabis/22/10/29175510/breaking-biden-announces-pardons-for-all-federal-marijuana-possession-convictions">Biden issued a general pardon </a>for previous crimes of simple cannabis possession in violation of federal law and the D.C. Code. In December 2023,<a href="https://www.benzinga.com/markets/cannabis/23/12/36361671/biden-pardons-thousands-convicted-of-cannabis-possession-calls-on-governors-to-do-the-same"> Biden expanded the pardon</a> to cover offenses for cannabis use and simple possession and called on state governors to do the same. 
Still nothing: There have been no pardons for federal inmates doing time for non-violent cannabis crimes. Beard Bros Pharm points out that Rubis "is not the only prisoner who fits that description but his continued incarceration is a reminder of the half-steps taken by this administration when it comes to cannabis reform and his immediate release would signal the Democratic Party&#8217;s commitment to future criminal justice reform."
Since he is not seeking re-election, President Biden has just over two months until Election Day and over four months until a new president is sworn in, "to right what he calls ‘historic wrongs&#8221; and grant Edwin Rubis a full presidential pardon.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/40846480/cannabis-experts-say-weed-reform-is-a-race-against-time-is-the-dea-delaying-bidens-rescheduling-">Cannabis Experts Say Weed Reform Is A Race Against Time, Is The DEA Delaying Biden&#8217;s Rescheduling Proposal?</a></li>
</ul>
Photo courtesy of Last Prisoner Project

Meet The Man Serving A 40-Year Sentence For Non-Violent Cannabis Charges, Awaiting Pardon From Biden

Investors in the cannabis sector are closely watching the potential rescheduling of cannabis by the DEA—a decision that could reshape the industry and unlock significant tax relief. As experts at a recent webinar discussed, the path forward hinges on a key Administrative Law Judge (ALJ) hearing scheduled for December 2, 2024, which could determine how quickly these changes will come and how much the market might shift.
<h3 class="wp-block-heading">Why Cannabis Reform Is Not A Priority In 2024</h3>
On September 11, 2024, Zuanic &amp; Associates hosted a comprehensive webinar focused on the ongoing process of cannabis rescheduling in the United States. Moderated by senior analyst <a href="https://www.benzinga.com/topic/pablo-zuanic">Pablo Zuanic</a> and Anthony Coniglio, CEO of (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NLCP#OTC">NLCP</a>), the panel featured industry experts Kelly Fair, a partner at Dentons, and Morgan Fox, the political director of the National Organization for the Reform of Marijuana Laws (NORML), the oldest cannabis reform organization in the U.S., founded in 1970.
Both panelists highlighted that while cannabis policy reform has gained traction among presidential candidates, it remains a secondary issue for the majority of voters.
Fox emphasized that although <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38905962/cannabis-rescheduling-when-will-it-happen-expert-lays-out-timeline-risks-and-wild-c">rescheduling</a> is a step in the right direction, NORML's ultimate goal is <a href="https://www.benzinga.com/markets/cannabis/23/04/31779376/exclusive-deschedulingrescheduling-cannabis-will-it-be-an-expeditious-path-to-280e-relief-this-i">full descheduling</a>. Fox suggested that descheduling would allow Congress to take meaningful steps toward regulating cannabis effectively, unlike the rescheduling process, which he deemed prone to political delays.
Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.
<h3 class="wp-block-heading">Who Gets To Speak At The Cannabis Hearing?</h3>
A significant portion of the discussion revolved around the technical aspects of the upcoming ALJ hearing. Fair clarified the procedural steps, noting that those wishing to speak must apply by September 30 with final speaker lists expected by November 2024.
Fair highlighted the importance of this hearing in shaping the final rescheduling rule, as it provides a platform for both proponents and opponents of the rescheduling proposal to present evidence. However, the panel agreed that the DEA retains substantial discretion in deciding the scope of the hearing and final rule.
Evidence and expert testimony presented during the<a href="https://www.benzinga.com/markets/cannabis/24/06/39436068/dea-18-gop-state-attorneys-general-want-public-hearing-on-cannabis-rescheduling-as-deadline-loom"> ALJ hearing</a> will play a pivotal role in shaping the DEA&#8217;s final decision on cannabis rescheduling. Both proponents and opponents of rescheduling will need to provide compelling arguments, as the DEA&#8217;s interpretation of this evidence could determine the outcome of the entire process.
<h3 class="wp-block-heading">Potential Delays And Challenges</h3>
Both Fox and Fair acknowledged that procedural hurdles and potential judicial challenges could prolong the timeline. Fox noted that any final ruling would likely face legal opposition, which could further <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40580306/cannabis-stocks-plummet-by-up-to-16-on-dea-rescheduling-delay-could-this-be-the-buy">delay implementation</a>. Fair added that while the ALJ's findings are essential, the DEA is not obligated to follow those recommendations, which adds another layer of uncertainty.
The webinar concluded with cautious optimism.
While rescheduling could provide some immediate relief, particularly by eliminating the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/08/33482140/rescheduling-cannabis-what-are-the-implications-for-msos-tax-rule-280e-fda-and-phar">280E tax burden</a>, the path forward remains uncertain due to potential political changes and judicial challenges. The panelists agreed that rescheduling is a step in the right direction but emphasized that descheduling remains the ultimate goal for meaningful cannabis reform.
Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/09/40712816/what-trump-learned-about-marijuana-that-desantis-did-not-and-why-the-gop-might-become-weed-frien">What Trump Learned About Marijuana That DeSantis Did Not And Why The GOP Might Become Weed-Friendly</a>

Exclusives

NLCP

Cannabis Experts Say Weed Reform Is A Race Against Time, Is The DEA Delaying Biden's Rescheduling Proposal?

MMJ BioPharma Cultivation finds itself at the center of a pivotal legal struggle with the Drug Enforcement Administration (DEA), accusing the agency of significant delays in processing its application to grow marijuana for pharmaceutical research. The company's<a href="https://www.benzinga.com/markets/cannabis/24/04/38182443/this-is-insanity-someones-got-to-act-marijuana-researcher-files-fed-lawsuit-against-dea-over-unc"> lawsuit</a> claims these delays have hindered critical clinical trials aimed at developing treatments for debilitating conditions such as Multiple Sclerosis (MS) and Huntington's Disease (HD), thereby prolonging the suffering of patients who could benefit from <a href="http://benzinga.com/topic/medical-cannabis">cannabis-based</a> therapies.
<h3 class="wp-block-heading">MMJ Struggles With DEA Delays</h3>
Duane Boise, president and CEO of MMJ International Holdings, explained to Benzinga that these delays have severely impacted the company's ability to cultivate the specific cannabis strains needed to produce active pharmaceutical ingredients (APIs). "Because the DEA has significantly delayed our DEA registration, MMJ has not been able to grow the specific marijuana plant cultivars utilized in the development of our API. There is currently no one in the United States growing specific cultivars to MMJ's pharmaceutical specifications," Boise noted. Even if MMJ could source these cultivars from other countries, it would still face roadblocks, as the company lacks the necessary DEA registration to process them within the U.S.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Investments And Clinical Trials Stalled By Federal Obstacles</h3>
The delays have not only impacted research but also deterred investors. "We have had investors ready to invest but when they saw the DEA roadblocks, it delayed the investment, thus extending the research timelines," Boise added. Despite these challenges, MMJ has successfully developed a soft gelatin capsule, <a href="https://www.benzinga.com/general/biotech/23/09/34770215/cannabis-research-company-submits-fda-responses-for-gel-capsule-approval">which is awaiting FDA approval</a>. Once approved, it will be used in human clinical trials, but for now, the company's research is in limbo.
Boise also addressed the Department of Justice&#8217;s (DOJ) argument that MMJ's lawsuit lacks subject-matter jurisdiction, explaining that the DEA has already conducted and completed its investigation in Rhode Island, where MMJ holds the required licenses. He contends that the DOJ's claim is a diversion tactic meant to confuse the court.
<h3 class="wp-block-heading">Constitutional Issues Raised In MMJ Case</h3>
MMJ's legal case <a href="https://www.accesswire.com/915174/mmj-biopharma-vs-dea-the-marijuana-rescheduling-scam-unveiled-a-defining-battle-for-federal-cannabis-reform-and-medical-research">raises</a> broader constitutional questions, particularly concerning the use of the Administrative Law Judges (ALJs) process used by the DEA in enforcement actions. Boise described the ALJ process as inherently biased: "When the Administrative Law Judge is judge, jury, and executioner how can this be impartial? The judge is blocking MMJ from questioning key DEA employees,&#8221; he remarked. Boise further emphasized that despite the <a href="https://www.benzinga.com/markets/cannabis/22/12/29944802/breaking-biden-signs-marijuana-research-bill-historic-moment-for-federal-cannabis-reform">marijuana research act</a>, which mandates a 90-day timeline for approval or denial, the judge has consistently failed to address the significant delays.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40823104/cannabis-companies-fight-federal-court-dismissal-on-prohibition-lawsuit-heading-to-next-legal-st">Cannabis Companies Fight Federal Court Dismissal On Prohibition Lawsuit, Heading To Next Legal Stop</a>
Moreover, MMJ BioPharma's legal position was bolstered by the <a href="https://www.benzinga.com/markets/cannabis/24/07/39598920/supreme-court-ruling-will-help-this-companys-battle-against-deas-kangaroo-court-and-anti-cannabi">recent Supreme Court ruling in Jarkesy v. SEC</a>, which reaffirmed the right to a jury trial in cases involving federal agency enforcement. Boise sees this ruling as a critical turning point. "A fair impartial trial will not take place unless the court abides by the recent Supreme Court ruling &#8211; Chevron Deference. Ambiguity in the law is not for the interpretation of the DEA, however, the truth is, and having a federal court recognize the truth is the end game."
<h3 class="wp-block-heading">MMJ BioPharma Committed To Long-Term Fight</h3>
Although these delays have altered MMJ's timeline, Boise made it clear that the company is in this fight for the long haul. "Yes, it has delayed our implementation by five years. We are prepared for the long haul and will maintain and persevere until the government decides to act in accordance with the law," he said. MMJ says it hopes the outcome of this case will set a precedent for both cannabis research and federal cannabis policy. "The DEA cannot continue to keep moving the goal post by their biased interpretations," Boise concluded.
The outcome of MMJ BioPharma's lawsuit could have far-reaching implications not just for the company's research, but for the broader <a href="http://benzinga.com/cannabis">cannabis industry</a>, especially as the <a href="https://www.benzinga.com/topic/cannabis-rescheduling">DEA's rescheduling</a> efforts progress.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/40804308/will-the-dea-complete-cannabis-rescheduling-hear-from-experts-the-day-after-harris-trump-debate">Will The DEA Complete Cannabis Rescheduling? Hear From Experts The Day After Harris-Trump Debate</a></li>
</ul>
Featured image generated with AI tools.

Interview

EXCLUSIVE: DEA Stalling Hinders Critical Clinical Trials For Debilitating Conditions, Says MMJ BioPharma CEO

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the real estate sector.
<h3 class="wp-block-heading">Easterly Government Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEA#NYSE">DEA</a>)</h3>
<ul>
<li>Dividend Yield: 7.99%</li>
<li>Truist Securities analyst Michael Lewis maintained a Hold rating and raised the price target from $13 to $14 on Aug. 29. This analyst has an accuracy rate of 70%.</li>
<li>RBC Capital analyst Michael Carroll downgraded the stock from Sector Perform to Underperform and cut the price target from $15 to $13 on Aug. 16, 2023. This analyst has an accuracy rate of 64%.</li>
<li>Recent News: On Sept. 5, Easterly Government Properties acquired 99,246 SF 100% leased to Northrop Grumman Systems.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091224&amp;t=be2bearmibe3na1"> latest DEA news. </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="908" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12070147/image-97.png" alt="" class="wp-image-544247" style="width:714px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12070147/image-97.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12070147/image-97-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12070147/image-97-768x709.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
<h3 class="wp-block-heading">Clipper Realty Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLPR#NYSE">CLPR</a>)</h3>
<ul>
<li>Dividend Yield: 7.44%</li>
<li>Raymond James analyst Buck Horne downgraded the stock from Outperform to Underperform on April 15. This analyst has an accuracy rate of 74%.</li>
<li>JMP Securities analyst Aaron Hecht downgraded the stock from Market Outperform to Market Perform on April 11. This analyst has an accuracy rate of 63%.</li>
<li>Recent News: On Aug. 1, Clipper Realty reported better-than-expected second-quarter revenue and FFO results.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091224&amp;t=be2bearmibe3na1"> trend in CLPR stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="918" height="846" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12070228/image-98.png" alt="" class="wp-image-544248" style="width:641px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12070228/image-98.png 918w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12070228/image-98-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12070228/image-98-768x708.png 768w" sizes="(max-width: 918px) 100vw, 918px" /></a></figure>
<h3 class="wp-block-heading">Park Hotels &amp; Resorts Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PK#NYSE">PK</a>)</h3>
<ul>
<li>Dividend Yield: 7.32%</li>
<li>Truist Securities analyst Patrick Scholes maintained a Buy rating and cut the price target from $20 to $18 on Sept. 4. This analyst has an accuracy rate of 70%.</li>
<li>UBS analyst Robin Farley maintained a Neutral rating and cut the price target from $18 to $14 on Aug. 16. This analyst has an accuracy rate of 84%.</li>
<li>Recent News: On July 31, Park Hotels &amp; Resorts posted weak quarterly sales.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091224&amp;t=be2bearmibe3na1">breakout in PK shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="867" height="831" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12071539/image-1-27.png" alt="" class="wp-image-544263" style="width:649px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12071539/image-1-27.png 867w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12071539/image-1-27-300x288.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12071539/image-1-27-768x736.png 768w" sizes="(max-width: 867px) 100vw, 867px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/09/40813043/jim-cramer-not-the-time-to-own-oil-when-asked-about-exxon-mobil-says-ibm-is-performing-well">Jim Cramer: &#8216;Not The Time To Own Oil,&#8217; When Asked About Exxon Mobil; Says IBM Is &#8216;Performing Well&#8217;</a></li>
</ul>

Wall Street's Most Accurate Analysts Spotlight On 3 Real Estate Stocks With Over 7% Dividend Yields

One day after the September Tuesday&#8217;s presidential debate, industry experts will break down the cannabis rescheduling process, a crucial issue for investors. Equity research firm Z&amp;A is hosting a <a href="https://zoom.us/webinar/register/WN_Jp3YHP7MSJGEeKrf2cL1eA#/registration">webinar</a> on Wednesday at 4:20 PM ET to provide insights into the upcoming regulatory shifts and market implications.
Get Benzinga's exclusive analysis and top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h3 class="wp-block-heading">DEA's Rescheduling Process</h3>
The conversation comes at a pivotal moment following the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39912859/as-election-buzz-swirls-around-biden-and-harris-dea-comment-period-ends-whats-next-">end of the public comment period</a> for the DEA to reschedule cannabis from Schedule I to Schedule III. Proposed by the Department of Justice on May 21 2024, the move was met with positive responses, as <a href="https://www.benzinga.com/markets/cannabis/24/05/39011156/exclusive-we-analyzed-4-000-dea-marijuana-rescheduling-comments-heres-what-americans-really-thin">75.9% of over 4,000 public comments </a>analyzed by Benzinga Cannabis showed support for rescheduling, mainly due to the medical benefits and alignment with state laws.
<h3 class="wp-block-heading">DEA Rescheduling Delay</h3>
On August 27, 2024, the DEA announced a delay in its final ruling until after the November election.
This triggered sharp declines in cannabis stocks, with the AdvisorShares Pure US Cannabis ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSOS#NYSE">MSOS</a>) <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40580306/cannabis-stocks-plummet-by-up-to-16-on-dea-rescheduling-delay-could-this-be-the-buy">dropping over 10%</a>. Major players like Curaleaf Holdings (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>), Cresco Labs (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>), and Cansortium (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) saw stock prices plunge by as much as 16%.
<h3 class="wp-block-heading">Investor's Angle: Upcoming Panel Post-Debate Chaos</h3>
If cannabis is reclassified, the industry could see significant changes such as tax reforms, enhanced research opportunities and the development of new regulatory frameworks.
This is where the insights from experts like Kelly Fair and Morgan Fox become crucial. Fair, a partner at Dentons, specializes in regulatory compliance and corporate governance within the cannabis sector. With nearly two decades of experience, she will provide in-depth perspectives on the technical aspects of the rescheduling process, the role of the DEA and possible legal outcomes. 
Meanwhile, Fox, the political director at NORML, will focus on the political landscape. With over 15 years of experience in cannabis policy reform, Fox will explain why descheduling remains the ultimate goal and how rescheduling fits into the bigger picture of cannabis reform.
Co-hosted by senior analyst <a href="https://www.benzinga.com/topic/pablo-zuanic">Pablo Zuanic </a>from Zuanic &amp; Associates, and Anthony Coniglio, CEO of NewLake Capital Partners (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NLCP#OTC">NLCP</a>), <a href="https://zoom.us/webinar/register/WN_Jp3YHP7MSJGEeKrf2cL1eA#/registration">the panel</a> promises to shed light on the future of cannabis regulation, particularly in light of the September 10th presidential debate.
Read Next:<a href="https://www.benzinga.com/markets/cannabis/24/09/40782415/top-dem-congressman-calls-trumps-cannabis-support-a-powerful-signal-to-gop-when-even-donald-trum"> Top Dem Congressman Calls Trump&#8217;s Cannabis Support A &#8216;Powerful Signal&#8217; To GOP: &#8216;When Even Donald Trump Can Get On Board…&#8217;</a>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Z&amp;A SPACES ON S3 RESCHEDULING: Dentons' Kelly Fair and NORML's Morgan Fox will discuss the technical and political aspects of S3 Rescheduling &amp; future developments (bifurcation? MMJ legalization? De-scheduling? Z&amp;A's <a href="https://twitter.com/420Odysseus?ref_src=twsrc%5Etfw">@420Odysseus</a> &amp; NLCP's <a href="https://twitter.com/AnthonyConigli0?ref_src=twsrc%5Etfw">@AnthonyConigli0</a> will host (Wed Sep 11 @… <a href="https://t.co/iMLzlfsIyE">pic.twitter.com/iMLzlfsIyE</a>
&mdash; Pablo Zuanic (@420Odysseus) <a href="https://twitter.com/420Odysseus/status/1832508687102951850?ref_src=twsrc%5Etfw">September 7, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>

CNTMF

CRLBF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

MSOS

Will The DEA Complete Cannabis Rescheduling? Hear From Experts The Day After Harris-Trump Debate

An U.S. appeals court has ruled that THC-O-acetate, a hemp-derived cannabinoid, is federally legal under the&nbsp;2018 Farm Bill. 
This ruling contradicts the position of the&nbsp;Drug Enforcement Administration (DEA) on legal cannabinoids, which had classified THC-O as a Schedule I controlled substance, <a href="https://www.marijuanamoment.net/thc-o-qualifies-as-legal-hemp-under-federal-law-appeals-court-says-rejecting-deas-restrictive-stance/">reported</a> Marijuana Moment.
The decision comes from the U.S. Court of Appeals for the Fourth Circuit.
<h3 class="wp-block-heading">The Case And Ruling</h3>
The case, which involved an employment dispute, hinged in part on the legal status of THC-O. A majority of the three-judge panel ruled that the <a href="https://www.benzinga.com/markets/cannabis/24/05/39046889/dea-rules-thca-is-not-legal-hemp-amid-industry-shake-up-and-farm-bill-debate-on-delta-8-thc-proh">DEA's interpretation </a>of the Farm Bill was too restrictive, saying that it does not apply to THC-O, a compound synthesized from legal hemp cannabinoids.
This decision builds on earlier rulings, particularly from the <a href="https://www.benzinga.com/markets/cannabis/23/10/35053162/court-orders-dea-to-respond-to-medical-marijuana-companys-request-for-bulk-manufacturing-registr">Ninth Circuit Court of Appeals</a>, which has previously ruled that cannabinoids like delta-8 THC are legal under the Farm Bill.
In its decision, the Fourth Circuit panel <a href="https://www.ca4.uscourts.gov/opinions/231400.P.pdf">wrote</a>, 
&#8220;The DEA's February 2023 letter clarified that THC-O doesn't occur naturally in the cannabis plant and can only be obtained synthetically, and therefore does not fall under the definition of hemp. However, the court found this interpretation overly restrictive and concluded that synthetically derived cannabinoids could still qualify as hemp under the 2018 Farm Bill if they contain less than 0.3 percent delta-9 THC.&#8221;
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40740888/missouris-hemp-battle-heats-up-as-governor-parson-revives-ban-in-a-mark-twain-like-drama">Missouri&#8217;s Hemp Battle Heats Up As Governor Parson Revives Ban In A Mark Twain-Like Drama</a>
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Federally Legal Cannabinoid</h3>
The judges emphasized their agreement with the Ninth Circuit's interpretation of the 2018 Farm Act, stating that the federal definition of hemp is clear and unambiguous. 
&#8220;We reject [the employer's] contention that the DEA's interim final rule mandates a finding that THC-O is illegal, agreeing instead with the Ninth Circuit's interpretation that products containing less than 0.3 percent delta-9 THC qualify as legal hemp regardless of whether they are synthetically derived,&#8221; ruled the judges.
Therefore, the ruling effectively counters the <a href="https://www.benzinga.com/markets/cannabis/23/02/30885046/delta-8-9-remains-a-controlled-substance-despite-hemp-bill-dea">DEA's February 2023</a> letter, which aimed to classify THC-O as illegal under federal law. The ruling might have broader implications for other cannabinoids, such as THCA.
If you&#8217;re interested in diving deeper into the consequences of the ongoing dispute between the cannabis and hemp THC industries, you might enjoy reading Benzinga&#8217;s series of <a href="https://www.benzinga.com/topic/hemp" target="_blank" rel="noreferrer noopener">articles</a> on the matter. We invite you to dive in!
<ul>
<li>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/09/40698576/navigating-hemp-vs-cannabis-debate-one-agenda-for-all-us-cannabis-councils-david-culver-weighs-i">Navigating Hemp Vs. Cannabis Debate: One Agenda For All? US Cannabis Council&#8217;s David Culver Weighs In</a></li>
</ul>
<h3 class="wp-block-heading"></h3>

U.S. Court Says This Cannabinoid Is Legal, Rejects DEA's Position On Controlled Substances

Real Estate

Easterly Government Properties Acquires 99,246 SF 100% Leased To Northrop Grumman Systems

The Mississippi State Legislature passed legislation Tuesday to establish the Mississippi Medical Cannabis Research Program at the University of Mississippi, marking a significant step forward in the study of <a href="http://benzinga.com/topic/medical-cannabis">medical marijuana</a> applications. Governor Tate Reeves (R) ratified the bill, which aims to deepen understanding of cannabis&#8217;s therapeutic potential and its impact on patient care.
<h3 class="wp-block-heading">Bipartisan Effort Supports Ole Miss's Legacy In Cannabis Research</h3>
Spearheaded by State Senator Kevin Blackwell (R) and co-authored by State Senators Reginald Jackson (D), Rod Hickman (D), Sarita Simmons (D) and Nicole Boyd (R), this initiative seeks to leverage Ole Miss&#8217;s longstanding expertise as a premier research institution. Historically, the University of Mississippi was the sole federally authorized cannabis cultivation site for research since 1968, a distinction that held until 2022 when the Drug Enforcement Administration (DEA) <a href="https://www.benzinga.com/markets/cannabis/22/01/24909785/dea-ends-5-decade-federal-monopoly-on-research-cannabis-production-approves-two-companies-to-har">authorized additional growers for research</a>.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter<a href="https://newsletteremail.benzinga.com/subscribe"> here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
&#8220;We are grateful for the leadership of Gov. Reeves and the tireless efforts of Sen. Blackwell, Sen. Boyd and their colleagues in championing this landmark legislation,&#8221; <a href="https://olemiss.edu/news/2024/09/medical-cannabis-research-program/index.html">said</a> Robert Welch, director of the university's National Center for Cannabis Research and Education (NCCRE) in a press release.
<h3 class="wp-block-heading">Bridging Cannabis Research With Health Policies</h3>
The program, housed in the university&#8217;s School of Pharmacy, will operate under the aegis of the newly established <a href="https://olemiss.edu/departments/pharmacy/national-cannabis-center/">NCCRE</a>. It will collaborate closely with the Mississippi Department of Health&#8217;s Mississippi Medical Cannabis Program and various patient advocacy groups to disseminate findings that are comprehensible to healthcare providers, patients, caregivers, law enforcement and policymakers.
<h3 class="wp-block-heading">Bill Secures Funding For Cannabis Research</h3>
The <a href="https://billstatus.ls.state.ms.us/2024/pdf/history/SB/SB2888.xml">bill</a> outlines the creation of an advisory board to oversee research compliance and strategic direction and provides the necessary funding to support scientific investigations. This funding is a pivotal component for exploring new therapeutic potentials and <a href="https://www.benzinga.com/topic/cannabis-education">educational initiatives</a> surrounding medical cannabis.
&#8220;The National Center for Cannabis Research and Education will help to ensure that Mississippi remains at the forefront of natural products research,&#8221; noted Senator Boyd. &#8220;I am proud of the University of Mississippi for continuing to be a national leader in research excellence.&#8221;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/07/39983822/cannabis-educational-content-should-be-incorporated-into-curricula-at-all-levels-says-american-c">Cannabis Educational Content Should Be Incorporated Into Curricula At All Levels, Says American College Of Physicians</a></li>
</ul>
Photo by Kevin Bain/Ole Miss Digital Imaging Services.

Education

Health Care

Cannabis Research Program At Ole Miss Approved, Funded By Mississippi Legislature

Return To Sender: Sell Postal Realty Trust

Here's the major earnings before the open tomorrow

Easterly Government GAAP EPS of $0.05

06:40 EST Easterly Government Properties (DEA) sees 2024 core FFO $1.15-$1.17, consensus $1.15 Published first on TheFly – the ultimate source for ...

Easterly Government Properties sees 2024 core FFO $1.15-$1.17, consensus $1.15

06:41 EST Easterly Government Properties (DEA) sees 2025 core FFO $1.17-$1.21, consensus $1.17 Published first on TheFly – the ultimate source for ...

Easterly Government Properties sees 2025 core FFO $1.17-$1.21, consensus $1.17

John Kim, an analyst from BMO Capital, maintained the Sell rating on Easterly Government Properties (DEA – Research Report). The associated price t...

Comments

Easterly Government Props

Notizie

Ultime notizie per Easterly Government Props (NYSE:DEA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO